[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Meiragtx Holdings Plc (MGTX)

Meiragtx Holdings Plc (MGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 739,530
  • Shares Outstanding, K 81,446
  • Annual Sales, $ 81,390 K
  • Annual Income, $ -114,200 K
  • EBIT $ -106 M
  • EBITDA $ -92 M
  • 60-Month Beta 1.27
  • Price/Sales 9.14
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 165.38% (+14.80%)
  • Historical Volatility 88.16%
  • IV Percentile 26%
  • IV Rank 15.38%
  • IV High 654.36% on 02/10/26
  • IV Low 76.50% on 07/30/25
  • Expected Move (DTE 16) 1.53 (16.85%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 10
  • Volume Avg (30-Day) 260
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 704
  • Open Int (30-Day) 2,668
  • Expected Range 7.55 to 10.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.43
  • Number of Estimates 4
  • High Estimate $0.16
  • Low Estimate $-0.75
  • Prior Year $-0.51
  • Growth Rate Est. (year over year) +15.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.01 +29.51%
on 03/30/26
11.85 -23.37%
on 04/15/26
+1.46 (+19.16%)
since 03/27/26
3-Month
6.62 +37.16%
on 03/05/26
11.85 -23.37%
on 04/15/26
+1.32 (+17.01%)
since 01/28/26
52-Week
4.55 +99.56%
on 05/14/25
11.85 -23.37%
on 04/15/26
+2.27 (+33.33%)
since 04/28/25

Most Recent Stories

More News
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten...

MGTX : 9.08 (-0.55%)
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)...

MGTX : 9.08 (-0.55%)
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts...

MGTX : 9.08 (-0.55%)
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for...

MGTX : 9.08 (-0.55%)
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract MeiraGTx to...

MGTX : 9.08 (-0.55%)
MeiraGTx Faces Mounting Losses as Analysts Await Fourth Quarter Results

Barchart Research What to Expect from MGTX Earnings MGTX Generated March 25, 2026 Current Price $7.62 EPS Estimate $-0.60 Consensus Rating Strong Buy Average Move 7.98% MeiraGTx Faces Mounting Losses as...

MGTX : 9.08 (-0.55%)
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy

BOSTON , Feb. 3, 2026 /PRNewswire/ -- ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (Nasdaq: MGTX),...

MGTX : 9.08 (-0.55%)
Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and...

MGTX : 9.08 (-0.55%)
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment...

MGTX : 9.08 (-0.55%)
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration...

MGTX : 9.08 (-0.55%)

Business Summary

MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR,...

See More

Key Turning Points

3rd Resistance Point 9.64
2nd Resistance Point 9.49
1st Resistance Point 9.29
Last Price 9.08
1st Support Level 8.94
2nd Support Level 8.79
3rd Support Level 8.59

See More

52-Week High 11.85
Last Price 9.08
Fibonacci 61.8% 9.06
Fibonacci 50% 8.20
Fibonacci 38.2% 7.34
52-Week Low 4.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.